US FDA sets panel review for Acorda's fampridine-SR in October
This article was originally published in Scrip
Executive Summary
The US FDA's peripheral and central nervous system drugs advisory committee will review Acorda's investigational product fampridine-SR (4-aminopyridine) on October 14th for the improvement of walking ability in people with multiple sclerosis. The FDA has given preliminary approval of the trade name Amaya for the product.